Clinical Trial Update: A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 [Phase 3]

View source ↗

Summary

Phase 3 master protocol study evaluating Orforglipron (LY3502970) in participants with hypertension and obesity; study is currently recruiting. This update refl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Obesity

Drugs mentioned

• Orforglipron (orforglipron)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Hypertension, Overweight or Obesity | Phase 3 | Status: RECRUITING